Shire Adds Two Pipeline Products With TKT Acquisition
Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate
Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate